Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Allergan, Inc. v. Teva Pharmaceuticals USA, Inc.
Case Number:
18-1130
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Government Agencies
Sectors & Industries:
-
February 15, 2019
Restasis Patent Redo Bid 'Inappropriate,' Fed. Circ. Told
The row over Allergan Inc.'s controversial deal to sell patents on the dry-eye drug Restasis to a Mohawk tribe to avoid the Patent Trial and Appeal Board continues, as generic makers on Thursday blasted Allergan's "inappropriate" bid for the Federal Circuit to reconsider its decision upholding the invalidity of its patents.
-
November 13, 2018
Fed. Circ. Won't Restore Allergan's Restasis Patent Claims
The Federal Circuit on Tuesday declined to restore invalidated patent claims for Allergan Inc.'s dry-eye drug Restasis, delivering a fresh boost to proposed generics of the blockbuster eye-drop medicine.
-
March 08, 2018
Don't Revive Restasis Patents, Generic Cos. Urge Fed. Circ.
A Texas federal judge rightly invalidated claims from four patents covering Allergan's dry-eye medicine Restasis, as they directly copied earlier patents the drugmaker had filed, a trio of generic-drug makers told the Federal Circuit in a brief unsealed Wednesday.
-
January 31, 2018
Axing Restasis Patents Would Stifle Innovation, PhRMA Warns
The Pharmaceutical Research and Manufacturers of America on Wednesday warned the Federal Circuit that allowing a district court to invalidate four patents tied to the dry-eye medication Restasis will block innovation in the pharmaceutical industry, as it undercuts protections tied to drugs being successful and filling a "long-felt need."
-
January 10, 2018
Allergan's Restasis Patents Are Valid, Fed. Circ. Told
The Saint Regis Mohawk Tribe, which acquired Allergan Inc.'s patents on the dry-eye drug Restasis, urged the Federal Circuit on Tuesday to reverse a ruling that invalidated four of its Restasis patents as obvious, arguing that the lower court's decision to ax the patents is "fraught with legal error."